A diagnosis of Netherton syndrome was made and the patient was started on antihistamines, emollients, and 10% urea. In our case, the patient presented at age 17 years. The history of his ...

Initial pediatric subject shows sustained benefit with QRX003; second patient approved for full-body treatment in ongoing ...

Quoin’s lead product candidate, QRX003, is currently being evaluated in four clinical trials for the treatment of Netherton Syndrome. The Company’s goal is to develop the first FDA-aproved therapy for ...

Quoin Pharmaceuticals (QNRX) announced the release of the second episode in its “Living with Netherton” video series, part of the company’s ...

"Why did my classmate say that my skin is yucky?" asked five-year-old Sophie Goh. It may seem like an innocent question, but ...

Target Indications Also Include Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma and Severe Atopic Dermatitis; Third Quoin Patent Application for Netherton Syndrome ; ...

Quoin Pharmaceuticals Ltd. has filed a U.S. patent application for new topical formulations aimed at treating several skin diseases, specifically Netherton Syndrome (NS) and Peeling Skin Syndrome.

Video features 79-year-old Norma Coles, believed to be among the earliest individuals ever evaluated for Netherton Syndrome and is available on the company's NETHERTON NOW website ASHBURN, Va., April ...

SAM Syndrome, Palmoplantar Keratoderma and Severe Atopic Dermatitis Third Quoin Patent Application for Netherton Syndrome If Granted Company Would have Patent Protection for QRX003 for Netherton ...

Quoin’s lead product, QRX003, is currently being tested in four Netherton Syndrome clinical trials. Three of these trials are being conducted under Quoin’s open Investigational New Drug (IND ...